PF-03550096

Summary

PF-03550096 is a drug that acts as a potent agonist for the CB2 cannabinoid receptor, with good selectivity over CB1 having Ki values of 7nM at CB2 and 1500nM at CB1. It was originally developed by Pfizer in 2008 as a medication for irritable bowel syndrome,[1] but has only progressed to animal studies.[2]

PF-03550096
Identifiers
  • N-[(1S)-1-(aminocarbonyl)-2,2-dimethylpropyl]-2,3-dihydro-3-(3-hydroxy-3-methylbutyl)-2-oxo-1H-benzimidazole-1-carboxamide
CAS Number
  • 910376-39-5 checkY
PubChem CID
  • 24857887
ChemSpider
  • 21378519
UNII
  • E8S33VNW75
CompTox Dashboard (EPA)
  • DTXSID001010008 Edit this at Wikidata
Chemical and physical data
FormulaC19H28N4O4
Molar mass376.457 g·mol−1
3D model (JSmol)
  • Interactive image
  • O=C(N1C(N(CCC(C)(O)C)C2=C1C=CC=C2)=O)N[C@@H](C(C)(C)C)C(N)=O
  • InChI=1S/C19H28N4O4/c1-18(2,3)14(15(20)24)21-16(25)23-13-9-7-6-8-12(13)22(17(23)26)11-10-19(4,5)27/h6-9,14,27H,10-11H2,1-5H3,(H2,20,24)(H,21,25)/t14-/m1/s1
  • Key:GGNIFXBIJCNXCT-CQSZACIVSA-N

See also edit

References edit

  1. ^ WO 2008032164, Ando K, et al, "Benzimidazolone Derivatives", published 20 March 2008, assigned to Pfizer Products Inc. 
  2. ^ Kikuchi A, Ohashi K, Sugie Y, Sugimoto H, Omura H (February 2008). "Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity". Journal of Pharmacological Sciences. 106 (2): 219–24. doi:10.1254/jphs.FP0071599. PMID 18270474.